The American Journal of Managed Care has posted a clinician perspective from Todd Schlesinger, MD, headlined "Balancing Efficacy and Tolerability in Skin Cancer Treatment." For a field with more tools than ever, that headline reads less like a topic and more like a check-in on a question that has quietly become harder to answer well.

The cases that test the question are not the textbook ones. They are the basal cell carcinoma on a 92-year-old on apixaban. The locally advanced cutaneous SCC where surgery would mean losing an ear. The thin melanoma that meets criteria for adjuvant PD-1 in a patient who cannot afford a year of fatigue. The Gorlin syndrome patient facing indefinite hedgehog inhibitor therapy and a lifetime of dysgeusia.

What does this change for you? The piece itself is a clinician essay, not a guideline revision. But it lands in a year when neoadjuvant cemiplimab is reshaping high-risk cutaneous SCC, when adjuvant PD-1 has become the default offer for stage III melanoma, and when payers are watching every adjuvant decision more closely than they ever have.

Schlesinger's headline says the quiet part out loud. Efficacy is no longer the only axis. Tolerability — and the patient's willingness to live with a given side-effect profile for a defined duration — now sits inside the decision from the first consult.

The skin cancer toolkit, in rough order of side-effect burden:

• Surgical excision and Mohs — defined morbidity, short recovery, done
• Topical 5-FU and imiquimod — local irritation, adherence headaches, often unfinished courses
• Photodynamic therapy — pain during treatment, generally well tolerated after
• Hedgehog inhibitors (vismodegib, sonidegib) — dysgeusia, alopecia, muscle cramps over months
• Immune checkpoint inhibitors — immune-related adverse events across nearly any organ system
• BRAF/MEK inhibitor combinations — fever, rash, arthralgias, secondary cutaneous events in a small share
• Radiotherapy — site-dependent, often under-discussed in dermatology clinics

Tolerability, in most of these, is not a footnote. It is the reason patients stop drugs that are working. It is the reason a 90-day topical course becomes 35 days. It is the reason a hedgehog inhibitor that visibly shrinks a tumor gets abandoned in month four. It is the reason an adjuvant pembrolizumab course ends after three cycles instead of thirteen.

None of that lives in the efficacy data. All of it lives in the patient's calendar.

There is also the patient context that no trial fully captures. The elderly patient with a low-risk BCC and a six-month life expectancy does not need the same answer as the 55-year-old with the same lesion. The patient who lives alone has a different surgery recovery than the one with a partner at home. The patient on multiple medications will experience checkpoint inhibitor toxicity differently than a trial cohort ever did.

Schlesinger's point, as the title telegraphs, is that the decision tree has a new branch. The branch is the patient — their age, their comorbidities, their support system, their tolerance for a specific kind of suffering. The oncologic call still anchors the choice. The tolerability call decides whether the patient finishes it.

That has practical weight. Shared decision-making visits are billable. Documenting the tolerability conversation, not just the efficacy one, is becoming a payer expectation in value-based arrangements and in pre-authorization reviews for the higher-cost agents. AJMC's audience knows this. The dermatology audience needs to keep hearing it.

The forward-looking question: as adjuvant indications grow and combination regimens become standard, tolerability — not efficacy — increasingly determines who finishes treatment. Schlesinger's short perspective sits at the front of that curve, and the dermatology community will be having the rest of the conversation for the next several years.